Shield Therapeutics is a well-funded, high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.
Shield has a rare opportunity to build an integrated, highly profitable specialty pharma business. In this section you can learn more about our lead product, and about our second asset.
Shield is well positioned to become a fast growing, independent, international specialty pharmaceutical company due to the strength of its products and team, and with great thanks to all of our supportive shareholders.
Our lead product, Feraccru®, is a novel oral treatment available via prescription for the treatment of Iron Deficiency with or without anaemia which has received marketing authorisation in the European Union and Switzerland. A New Drug Application (NDA) for Feraccru® was submitted to the US Food & Drug Administration (FDA) in September 2018 and the application has a PDUFA (Prescription Drug Users Fee Act) date of 27th July 2019.
Please click here for more information on PT20, PT30 and PT40.
